我国第二批重点监控合理用药药品管理政策分析  

Analysis on the Management Policies of the Second Catalog of Key Monitoring andRational Use Drug

作　　者：贺雯茜 刘东[1] 余爱荣 赵琳琳 HE Wenxi;LIU Dong;YU Airong;ZHAO Linlin(Department of Pharmacy,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Clinical Pharmacy,General Hospital of Central Theatre Command,Wuhan 430070,China)

机构地区：[1]华中科技大学同济医学院附属同济医院药学部,武汉430030 [2]中部战区总医院临床药学科,武汉430070

出　　处：《医药导报》2024年第7期1170-1176,共7页Herald of Medicine

摘　　要：目的 分析国家及不同省(自治区、直辖市)第二批国家重点监控合理用药药品目录与管理政策,为医疗机构制定本院重点监控合理用药药品目录及管理政策提供参考。方法 以“重点监控”“合理用药”“第二批”等为关键词,检索国家及各省级卫生健康行政部门官方网站,下载并整理发布的重点监控合理用药药品目录及相关政策文件。分析国家重点监控合理用药目录变化,比较各省第二批重点监控合理用药药品目录;分析国家重点监控合理用药药品管理政策在各省执行情况及各省重点监控合理用药药品管理政策异同。结果 国家第二批重点监控合理用药药品目录与第一批相比,有7个品种被继续纳入,13个品种被移出,23个品种被新纳入。24个省第二批重点监控合理用药药品目录与国家第二批重点监控合理用药药品目录相比,有9个省对省级目录进行调整,共计66个药物品种,涉及10个药物解剖学-治疗学-化学(ATC)分类,其中系统用感染药纳入品种最多。新疆、内蒙古、辽宁、上海、青海等省新增“制定临床应用指南”“明确临床应用条件和原则”等管理政策与措施。此外,内蒙古、山东、吉林和黑龙江4个省制定了重点监控合理用药药品监测指标,丰富了重点监控合理用药药品管理工具箱。第一批与第二批重点监控合理用药药品目录纳入规则调整之后,大量临床必需药品纳入目录,医疗机构沿用第一批目录阶段“一刀切”踢出用药目录的做法不再可行,将影响医疗机构药品正常供应,甚至提高治疗费用。结论 医疗机构应把握重点监控合理用药药品新内涵,借鉴相关省建立监测指标管理的方式,参考临床应用指南,明确临床应用的条件和原则,通过处方审核和处方点评手段,实现对重点监控合理用药药品的院内监测、评价和超常预警,科学管理重点监控合理用药药品。Objective To evaluate the second catalog of the key monitoring and rational use drugs(KMRUD),and to provide a reference framework for medical institutions to develop their own KMRUD catalogs and management policies.Methods A comprehensive search on official websites of national and provincial health administrative departments was conducted using the keywords“key monitoring”,“rational drug use”,and“the second catalog”.Announced catalogs and related policy documents pertaining to KMRUD use were collected and systematically organized.Comparative analyses were performed between the national KMRUD catalogs of the first and second batches,as well as between the second batch of provincial KMRUD catalogs and the national standard.Additionally,the adoption and variation of national KMRUD drug management policies across provinces,as well as the uniformity and divergence of provincial KMRUD management policies,were examined.Results The second national KMRUD catalog maintained 7 drug varieties from the first batch,eliminated 13,and introduced 23 new varieties.Of the 24 surveyed provinces,9 modified their provincial catalogs relative to the national second batch KMRUD catalog,resulting in alterations to 66 drug varieties within 10 Anatomical Therapeutic Chemical(ATC)classes,primarily systemic antiinfectives.Several provinces,including Xinjiang,Inner Mongolia,Liaoning,Shanghai,and Qinghai,implemented additional management measures such as the establishment of clinical application guidelines and the clarification of application conditions and principles.Moreover,provinces like Inner Mongolia,Shandong,Jilin,and Heilongjiang expanded their KMRUD management toolbox by developing drug monitoring indicators.The revision of inclusion rules from the first to the second KMRUD catalog has led to the incorporation of numerous essential clinical drugs.The prior protocol of medical institutions excluding drugs unilaterally is no longer viable,as it may disrupt the standard medication supply,potentially raising treatment costs.C

关 键 词：第二批国家重点监控合理用药药品目录 重点监控 药品目录 合理用药 政策管理 

分 类 号：R95[医药卫生—药学]